Collaboration in Access
& Reimbursement Essentials
JETREA CARE® is the ThromboGenics®
reimbursement support services platform with a variety of financial assistance programs for all qualifying patients.
JETREA® (ocriplasmin) Intravitreal Injection, 2.5 mg/mL, is a proteolytic enzyme indicated for the treatment of
symptomatic vitreomacular adhesion.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088. You may also report side effects of JETREA online directly to ThromboGenics by clicking here if you are a Patient or here if you are a Health Care Professional.